Form 4: Director and 10% Owner James E. Flynn Sells Over 740,000 ARS Pharmaceuticals Shares

James E. Flynn, a director and 10% owner of ARS Pharmaceuticals, Inc., along with affiliated Deerfield entities, reported the sale of 740,149 shares of Class A Common Stock for approximately $13.66 million.

Summary

• James E. Flynn, a director and 10% owner of ARS Pharmaceuticals, Inc. (SPRY), reported the sale of 740,149 shares of Class A Common Stock on June 27, 2025.
• The shares were sold at a weighted average price of $18.46 per share, with prices ranging from $18.20 to $18.89.
• The total value of the shares sold is approximately $13,660,759.54 (740,149 shares * $18.46/share).
• Following these transactions, the reporting persons beneficially own 4,887,254 shares indirectly through Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• The filing indicates that James E. Flynn is the sole member of the general partner of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., and Deerfield Management Company, L.P., which manage the funds holding the shares.

Sentiment

Score: 5

Explanation: A score of 5 (neutral) is assigned because while insider selling can be perceived negatively, the disclosure that it was conducted under a Rule 10b5-1 plan suggests it was a pre-planned transaction, mitigating the immediate negative signal often associated with opportunistic insider sales. The large volume, however, prevents a higher score.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to new, negative information.

Negatives

• A significant sale of 740,149 shares by a director and 10% owner could be perceived as a negative signal by investors, potentially indicating a lack of confidence or a move to diversify holdings.
• The sale represents a substantial amount of capital being divested from the company by a key insider.

Risks

• Investor perception risk: Large insider sales, even if pre-planned, can sometimes lead to negative market sentiment or speculation about the company's future prospects.
• Potential for increased selling pressure if other insiders or institutional investors follow suit.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

This Form 4 filing reports an insider transaction specific to ARS Pharmaceuticals, Inc. and its affiliated investment entities. It does not provide broader industry trends or competitive analysis. However, insider selling activity in a biotechnology or pharmaceutical company can sometimes be scrutinized more closely given the binary nature of clinical trial outcomes and regulatory approvals.

Comparison to Industry Standards

• This document reports an insider stock transaction and does not contain information suitable for comparison to global industry benchmarks, specific comparable companies, projects, or results. Such comparisons would typically be found in financial reports (e.g., 10-K, 10-Q) or investor presentations.

Related Party Transactions

• The sale of shares by James E. Flynn, a director and 10% owner, and the affiliated Deerfield entities (Deerfield Management Company, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P.) constitutes a related party transaction. James E. Flynn is the sole member of the general partner of the managing entities of the funds involved in the sale.

Stakeholder Impact

• Shareholders: The sale by a significant insider and 10% owner could lead to concerns about management's confidence in the company's future, potentially influencing stock price and investor sentiment.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing, as its purpose is to report a completed insider transaction.

Key Dates

Recommendation

Keywords

ARS Pharmaceuticals, SPRY, SEC Form 4, Insider Selling, Stock Sale, James E. Flynn, Deerfield Management, 10b5-1 Plan, Beneficial Ownership, Biotechnology, Pharmaceuticals